
- /
- Supported exchanges
- / US
- / VRCA.NASDAQ
Verrica Pharmaceuticals Inc (VRCA NASDAQ) stock market data APIs
Verrica Pharmaceuticals Inc Financial Data Overview
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Verrica Pharmaceuticals Inc data using free add-ons & libraries
Get Verrica Pharmaceuticals Inc Fundamental Data
Verrica Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 7 179 K
- EBITDA: -53 734 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.136
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Verrica Pharmaceuticals Inc News

Verrica Pharmaceuticals reports 32.8% quarterly growth in YCANTH sales
WEST CHESTER, Pa. - Verrica Pharmaceuticals Inc. (NASDAQ:VRCA), a pharmaceutical company with a market capitalization of approximately $80 million, dispensed a record 13,434 units of its YCANTH applic...


Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
Verrica Pharmaceuticals Inc. – Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the mos...

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for ...

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
– Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4’24 concurrent with significantly lower operating expenses – – Company reports positive qu...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.